vTv Therapeutics Inc. (NASDAQ:VTVT) Short Interest Up 37.1% in April

vTv Therapeutics Inc. (NASDAQ:VTVT) was the target of a large increase in short interest in April. As of April 15th, there was short interest totaling 112,740 shares, an increase of 37.1% from the March 31st total of 82,236 shares. Based on an average daily trading volume, of 53,225 shares, the short-interest ratio is currently 2.1 days. Approximately 3.0% of the company’s shares are sold short.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of vTv Therapeutics in a report on Friday, March 27th. Wall Street Zen upgraded vTv Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, March 14th. TD Cowen assumed coverage on vTv Therapeutics in a report on Monday, January 5th. They set a “buy” rating for the company. Evercore assumed coverage on vTv Therapeutics in a report on Thursday, March 12th. They set an “outperform” rating and a $44.00 target price for the company. Finally, Roth Mkm assumed coverage on vTv Therapeutics in a report on Thursday, January 22nd. They set a “buy” rating and a $58.00 target price for the company. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, vTv Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $53.00.

Hedge Funds Weigh In On vTv Therapeutics

A number of large investors have recently modified their holdings of the business. Baker BROS. Advisors LP boosted its stake in shares of vTv Therapeutics by 52.4% during the 3rd quarter. Baker BROS. Advisors LP now owns 148,314 shares of the biotechnology company’s stock worth $3,463,000 after buying an additional 51,000 shares during the last quarter. Geode Capital Management LLC lifted its stake in vTv Therapeutics by 84.3% in the 4th quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock valued at $1,128,000 after purchasing an additional 12,896 shares during the last quarter. 683 Capital Management LLC acquired a new stake in vTv Therapeutics in the 4th quarter valued at about $731,000. Finally, Goldman Sachs Group Inc. acquired a new stake in vTv Therapeutics in the 4th quarter valued at about $221,000. 17.51% of the stock is currently owned by institutional investors and hedge funds.

vTv Therapeutics Trading Down 0.6%

Shares of vTv Therapeutics stock traded down $0.20 during trading hours on Thursday, reaching $31.08. 5,126 shares of the company’s stock were exchanged, compared to its average volume of 46,563. The company has a 50 day moving average of $36.77 and a two-hundred day moving average of $33.29. vTv Therapeutics has a fifty-two week low of $14.00 and a fifty-two week high of $44.00. The stock has a market cap of $122.40 million, a P/E ratio of -9.28 and a beta of 0.40.

vTv Therapeutics (NASDAQ:VTVT) last posted its quarterly earnings data on Tuesday, March 10th. The biotechnology company reported ($0.58) EPS for the quarter, topping analysts’ consensus estimates of ($1.09) by $0.51. As a group, analysts expect that vTv Therapeutics will post -2.66 earnings per share for the current fiscal year.

About vTv Therapeutics

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.